Synairgen (LON:SNG) Trading 6.2% Higher – Still a Buy?

Synairgen plc (LON:SNG) shares traded up 6.2% during mid-day trading on Tuesday . The stock traded as high as GBX 1.20 ($0.02) and last traded at GBX 0.90 ($0.01). 293,563 shares changed hands during trading, a decline of 80% from the average session volume of 1,453,790 shares. The stock had previously closed at GBX 0.85 ($0.01).

Synairgen Stock Up 6.2 %

The firm has a market cap of £8.83 million, a price-to-earnings ratio of -0.54 and a beta of -2.23. The company’s 50-day moving average price is GBX 1.94 and its 200-day moving average price is GBX 3.27.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).